This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Quality of Care, Other  • Alert me on articles by topic

The Informed View

Arch Dermatol. 1999;135:1255-1259.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THIS ISSUE of the ARCHIVES presents an ideal opportunity to review 2 important topics in cutaneous oncology: the use of Mohs micrographic surgery (MMS) for skin cancer excision and the management of primary basal cell carcinoma (BCC). In their study, Thissen et al¹ attempt to compare the effectiveness of 7 treatment modalities for primary BCC. While their study confirms much of what we already know, the authors raise important questions about our assumptions regarding the demonstrable effectiveness of these modalities. Likewise, in the article by Rosai,² he stimulates discussion about the histopathological skills of surgeons who perform MMS. A critical analysis of the article by Thissen et al¹ interestingly converges with concepts of treatment efficacy addressed by Rosai.²

Thissen and colleagues¹ sought to develop evidence-based guidelines for the treatment of primary BCC. They limited their analysis to prospective studies performed after 1970 that tracked 50 or more lesions for 5 . . . [Full Text of this Article]

RECURRENCE RATE REPORTING: CAVEAT LECTOR


DO WE NEED A PROSPECTIVE, RANDOMIZED STUDY COMPARING PRIMARY BCC TREATMENT METHODS?

WHAT DO WE KNOW ABOUT TREATING PRIMARY BCC?
Location

Size

Histological Considerations

Tissue Preservation

Cost

ARE RECURRENCE RATES THE "GOLD STANDARD" FOR CHOOSING A TREATMENT METHOD?

CAN MOHS SURGEONS, IN FACT, DO MOHS SURGERY?

WHO TRULY HAS MORE EXPERIENCE INTERPRETING CUTANEOUS HISTOPATHOLOGIC CASES?

WHERE IS DERMATOPATHOLOGY'S HOME?

QUALITY CONTROL AND QUALITY ASSURANCE FOR THE MOHS SURGEON

DARE WE READ OUR OWN SLIDES?

RELATED ARTICLES

Mohs Micrographic Surgery: A Pathologist's View
Juan Rosai
Arch Dermatol. 1999;135(10):1171-1173.
EXTRACT | FULL TEXT  

A Systematic Review of Treatment Modalities for Primary Basal Cell Carcinomas
Monique R. T. M. Thissen, Martino H. A. Neumann, and Leo J. Schouten
Arch Dermatol. 1999;135(10):1177-1183.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Determining the value of surgical therapies for Basal cell carcinoma.
Chren
Arch Dermatol 2006;142:231-232.
FULL TEXT